Stage III Prostate Cancer AJCC v8

general

Stage IIIA includes: T1-2, N0, M0, PSA 20 or more, Grade Group 1-4; T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleas

73

Centers

193

Active Trials

Cancer Funding

Specific Cancer Types(2)

Top Centers for Stage III Prostate Cancer AJCC v8(73)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
72.9
2
High-Volume Research Center
72.3
3
NCI Comprehensive
Active Research Program
69.8
469.8
5
NCI Comprehensive
Active Research Program
69.8
6
NCI Comprehensive
Active Research Program
69.8
7
NCI Comprehensive
Active Research Program
69.8
8
Active Research Program
69.8
9
Active Research Program
69.8
10
NCI Comprehensive
Active Research Program
61.8
11
NCI Comprehensive
Active Research Program
61.8
12
NCI Comprehensive
Active Research Program
61.8
13
NCI Comprehensive
Active Research Program
61.8
14
NCI Comprehensive
Active Research Program
61.8
15
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
Active Research Program
61.8
16
NCI Comprehensive
Active Research Program
61.8
17
NCI Comprehensive
Active Research Program
61.8
18
Active Research Program
61.8
19
NCI Clinical
Active Research Program
61.8
20
Active Research Program
61.8
21
NCI Clinical
Active Research Program
61.8
22
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
Active Research Program
61.8
23
Active Research Program
61.8
24
Active Research Program
61.8
25
Active Research Program
61.8
26
Active Research Program
61.8
27
Active Research Program
61.8
28
Active Research Program
61.8
29
NCI Comprehensive
Active Research Program
48.5
30
NCI Comprehensive
Active Research Program
48.5
31
NCI Comprehensive
Active Research Program
48.5
32
NCI Comprehensive
Active Research Program
48.5
33
NCI Comprehensive
Active Research Program
48.5
34
NCI Clinical
Active Research Program
48.5
35
NCI Comprehensive
Active Research Program
48.5
36
NCI Clinical
Active Research Program
48.5
37
NCI Comprehensive
Active Research Program
48.5
38
NCI Comprehensive
Active Research Program
48.5
39
Cedars-Sinai CancerLos Angeles, CA
Active Research Program
48.5
40
NCI Comprehensive
Active Research Program
48.5
41
NCI Comprehensive
Active Research Program
48.5
42
NCI Clinical
Active Research Program
48.5
43
NCI Comprehensive
Active Research Program
48.5
44
NCI Comprehensive
Active Research Program
48.5
4548.5
46
Active Research Program
48.5
47
Active Research Program
48.5
48
Active Research Program
48.5
49
Active Research Program
48.5
50
Active Research Program
48.5
51
Active Research Program
48.5
52
Active Research Program
48.5
53
NCI Comprehensive
Active Research Program
35.3
54
NCI Comprehensive
Active Research Program
35.3
55
NCI Comprehensive
Active Research Program
35.3
56
NCI Comprehensive
Active Research Program
35.3
57
NCI Comprehensive
Active Research Program
35.3
58
NCI Comprehensive
Active Research Program
35.3
59
NCI Comprehensive
Active Research Program
35.3
60
NCI Comprehensive
Active Research Program
35.3
61
NCI Comprehensive
Active Research Program
35.3
62
NCI Comprehensive
Active Research Program
35.3
63
NCI Comprehensive
Active Research Program
35.3
64
NCI Comprehensive
Active Research Program
35.3
65
NCI Comprehensive
Active Research Program
35.3
66
NCI Comprehensive
Active Research Program
35.3
67
NCI Comprehensive
Active Research Program
35.3
68
NCI Comprehensive
Active Research Program
35.3
69
NCI Comprehensive
Active Research Program
35.3
70
Active Research Program
35.3
71
Active Research Program
35.3
72
NCI Comprehensive
28.8
7328.8

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →